Navigation Links
Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
Date:4/25/2008

SAN DIEGO, April 25 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Morgan Stanley Global Healthcare Unplugged Conference in Key Biscayne, FL on Thursday, May 1, 2008 at 9:20 a.m. ET / 6:20 a.m. PT. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview.

The live presentation and breakout session will be webcast, and a recording will be made available following the event. The webcast and recording will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 1,900 employees nationwide. Further information on Amylin Pharmaceuticals is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... Irvine, CA (PRWEB) March 04, 2015 ... research leader in Personalized Medicine, is excited to ... “Incorporating Genetic Testing to Optimize the Management of ... be available at Medscape.com for the next year. ... medical professionals how to recognize inadequate pain treatments, ...
(Date:3/4/2015)... March 04, 2015 Follow us ... one of the fastest growing technologies in the life ... subcellular visualization is driving growth in nucleic acid detection ... understanding of gene expressions will continue to benefit the ... in fields ranging from pharma, biotech, food & beverage ...
(Date:3/3/2015)... 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, ... molecular diagnostics that target the underlying mechanisms of cancer, ... period ended December 31, 2014. Effective July ... from May 31 to December 31. As a result ... are for the quarter and the seven months ended ...
(Date:3/3/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced several ... projects in North America , the ... "Bidding activity in 2015 continues to be robust" said ... year for bidding in 2014, we are pleased to see the ... the organization,s renewed focus on select market segments where we can ...
Breaking Biology Technology:Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12
... an individual becomes infected with HIV the virus infects ... nervous system [CNS]). Although this causes no immediate problems, ... and encephalitis (acute inflammation of the brain that can ... (SIV) also sometimes develop CNS damage and provide a ...
... A genetic tool used by medical researchers may also be ... viruses from drinking water. , In a series of proof-of-concept ... material could successfully target a matching portion of a gene ... stop working. If this new approach can be perfected, the ...
... Exponent, Inc.,(Nasdaq: EXPO ) announced today ... an additional $35,000,000 for the repurchase of Exponent,s ... transactions in compliance,with Securities and Exchange Commissions Rule ... the future cash flow of the,Company, as well ...
Cached Biology Technology:Possible new approach to purifying drinking water 2Possible new approach to purifying drinking water 3Exponent Adds $35 Million to Stock Repurchase Program 2
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/9/2015)...  Lintec of America recently announced an exclusive license ... macrostructures, including sheets, yarns and ribbons, developed at the ... the vast industrial resources of the global Lintec Group, ... of America is forming the Nano-Science and Technology Center ... on scaling up the manufacturing and commercialization of nano ...
(Date:2/5/2015)... IRVINE, Calif. , Jan. 27, 2015 ... trusted provider of globally deployed, innovative test ... today announced the delivery of its ... Martin Space Systems Company (LMSSC). GENASYS is ... the demands of mission-critical applications that require ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... ,A new EU project, METSY, develops and applies ... metabolism is connected to psychotic disorders and metabolic ... The overall objective is to identify, prioritize and ... diagnostic potential for prediction and monitoring psychotic disorders ...
... by ChipCare Corporation, has secured one of the ... Phase II financing has closed, with an investment ... commercialization over the next three years. The ... among Canadian social angel investors, including Maple Leaf ...
... of Geneva (UNIGE),s Faculty of Medicine in the context of ... the genetic causes of differences between people. The study, published ... the largest-ever dataset linking human genomes to gene activity at ... genome makes them more or less susceptible to disease is ...
Cached Biology News:ChipCare's handheld analyzer attracts one of Canada's largest-ever healthcare angel investments 2Functional genetic variation in humans: Comprehensive map published 2
BD BioCoat BD MatrigelTM Matrix 100 mm Culture Dishes for hepatocytes, tissue-culture treated polystyrene with a uniform application of MATRIGEL Matrix....
... used as an internal standard for the ... mass spectrometry. 5-OxoETE is a polyunsaturated keto ... in human neutrophils. It stimulates cytosolic calcium ... 2 nM. 5-OxoETE selectively stimulates the migration ...
... 5-OxoETE-d7 is used as an internal ... stable isotope dilution mass spectrometry. 5-OxoETE is ... oxidation of 5-HETE in human neutrophils. It ... an EC50 of 2 nM. 5-OxoETE selectively ...
... Mouse monoclonal antibody raised against ... Immunogen: HD ... a.a) partial recombinant protein with ... Accession Number: NM_002111 ...
Biology Products: